



Rheumatoid Arthritis

OVERVIEW

The US biologics and small molecule market for the treatment of rheumatoid arthritis (RA) is well established with a variety of drugs and mechanisms of action for treatment. Though the backbone TNF-inhibiting biologics have dominated the space for nearly two decades, more recent launches, an active pipeline, and the imminent introduction of Biosimilars present an opportunity for major future shifts in the RA landscape.

The **RealTime Dynamix Rheumatoid Arthritis** report series provides a detailed and timely look at current and future trends in the RA market, and the effects of the future shifting landscape. The quarterly releases allow for close monitoring and trending of key performance metrics. In addition to the fixed trended measures, the report also includes variable content addressing key current issues that is refreshed quarterly. The rapid field-to-insight turnaround time, highly relevant content, and unparalleled knowledge of the Rheumatology market make this an essential tool for companies competing in the space, as well as those with near term plans to enter it.

SAMPLE & METHODOLOGY

The report is based on an online survey of 100 US rheumatologists and is fielded on a quarterly basis. Respondents are recruited from the Spherix Network, a proprietary group of clinical rheumatologists meeting quality screening criteria. Our relationship with this network leads to more engaged respondents resulting in higher quality output.

KEY QUESTIONS ANSWERED

- What is the current and future landscape of the RA biologic/JAK market?
- What brands are expected to grow, and at the expense of what other brands?
- What are the critical opportunities and barriers to growth?
- What is the rheumatologist's perception of late stage pipeline assets and how do they anticipate incorporating these assets into their RA treatment?
- What are the representative contact rates for brands?
- What are rheumatologist's opinions and views on key market events?

Products Profiled:

Commercial Products:

Genentech's Actemra (tocilizumab), UCB's Cimzia (certolizumab), Amgen's Enbrel (etanercept), AbbVie's Humira (adalimumab), BMS' Orencia (abatacept), Janssen's Remicade (infliximab), Biogen Idec's Rituxan (rituximab), Janssen's Simponi (golimumab), Pfizer's Xeljanz (tofacitinib)

Pipeline Agents:

Incyte and Eli Lilly's Baricitinib, Regeneron and Sanofi's Sarilumab, GSK and Janssen's Sirukumab

Key Dates:

Report Series Published:

Q2 - June 30th, Q3 - September 30th, Q4 - December 30th 2016

Comments and proprietary questions due on the 12th of the first month of each quarter.

Deliverables:

- PowerPoint report
- Frequency Tables & Summary Statistics
- On-site presentation

Related Reports:

- RealWorld Dynamix: Biologic Switching in Rheumatoid Arthritis US April 29th 2016